Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Grubert

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
American Journal of Botany|July 16, 1999
The architecture of Mourera fluviatilis (Podostemaceae): developmental morphology of inflorescences, flowers, and seedlingsR Rutishauser, M Grubert
Biophysical Chemistry|September 1, 1981
A comparative calorimetric study on tRNA unfoldingF J Schott, M Grubert, W Wangler, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 11, 2009
Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumorsH Richly, M Grubert, M E Scheulen, et al.
Phytochemistry|December 1, 1994
Bioactive chromenes from Rhyncholacis penicillataG Burkhardt, H Becker, M Grubert, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 25, 2003
The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOHH J Müller, R E Port, M Grubert, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 31, 2002
The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and HematologyH J Müller, M Grubert, R Hilger, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 24, 2005
Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/DoxilR A Hilger, H Richly, M Grubert, et al.
Medical Hypotheses|January 6, 2020
Does SEN-V and other non-A-E hepatotropic viruses contribute to the development and progression of non-alcoholic fatty liver disease?M Grubert Van Iderstine, C Osiowy, C Rumbolt, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 11, 2009
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysisR A Hilger, H Richly, M Grubert, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 10, 2005
Impact of continuous and pulsatile insulin delivery on net hepatic glucose uptakeJaime M Grubert, Margaret Lautz, D Brooks Lacy, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
American Journal of Botany|July 16, 1999
The architecture of Mourera fluviatilis (Podostemaceae): developmental morphology of inflorescences, flowers, and seedlingsR Rutishauser, M Grubert
Biophysical Chemistry|September 1, 1981
A comparative calorimetric study on tRNA unfoldingF J Schott, M Grubert, W Wangler, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 11, 2009
Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumorsH Richly, M Grubert, M E Scheulen, et al.
Phytochemistry|December 1, 1994
Bioactive chromenes from Rhyncholacis penicillataG Burkhardt, H Becker, M Grubert, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 25, 2003
The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOHH J Müller, R E Port, M Grubert, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 31, 2002
The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and HematologyH J Müller, M Grubert, R Hilger, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 24, 2005
Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/DoxilR A Hilger, H Richly, M Grubert, et al.
Medical Hypotheses|January 6, 2020
Does SEN-V and other non-A-E hepatotropic viruses contribute to the development and progression of non-alcoholic fatty liver disease?M Grubert Van Iderstine, C Osiowy, C Rumbolt, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 11, 2009
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysisR A Hilger, H Richly, M Grubert, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 10, 2005
Impact of continuous and pulsatile insulin delivery on net hepatic glucose uptakeJaime M Grubert, Margaret Lautz, D Brooks Lacy, et al.
Pageof 2